The Year in Hypertension

Journal of the American College of Cardiology

Volumn 51, Issue 18, 2008, Pages 1803-1817

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ALISKIREN; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANYLATE CYCLASE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; PROPRANOLOL; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUPUNCTURE; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTERIAL STIFFNESS; ARTERY DISEASE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; BODY MASS; BREAST DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CROSS LINKING; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EYE DISEASE; GASTROINTESTINAL HEMORRHAGE; GENE IDENTIFICATION; GENE MUTATION; GYNECOMASTIA; HAZARD RATIO; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART SIZE; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MARFAN SYNDROME; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NEOPLASM; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; REVIEW; SALT INTAKE; SLEEP; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIFE STYLE; PROGNOSIS; RISK FACTORS; STROKE;

EID: 42949127526     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.010     Document Type: Review

References (115)

1. Williams B. The year in hypertension. J Am Coll Cardiol 48 (2006) 1698-1711
2. Kikuya M., Hansen T.W., Thijs L., et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 115 (2007) 2145-2152
3. Kawabe H., and Saito I. Which measurement of home blood pressure should be used for clinical evaluation when multiple measurements are made?. J Hypertens 25 (2007) 1369-1374
4. Padfield P.L., and Parati G. Home blood pressure monitoring in clinical practice: how many measurements and when?. J Hypertens 25 (2007) 1337-1339
5. O'Brien E., O'Brien E., Asmar R., et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21 (2003) 821-848
6. Mancia G., Facchetti R., Bombelli M., Grassi G., and Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 47 (2006) 846-853
7. Hara A., Ohkubo T., Kikuya M., et al. Detection of carotid atherosclerosis in subjects with masked hypertension and whitecoat hypertension by self-measured blood pressure at home: the Ohasama study. J Hypertens 25 (2007) 321-327
8. Williams B., Lacy P.S., Thom S.M., et al., CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 113 (2006) 1213-1225
9. Roman M.J., Devereux R.B., Kizer J.R., et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart study. Hypertension 50 (2007) 197-203
10. Agabiti-Rosei E., Mancia G., O'Rourke M.F., et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 50 (2007) 1-7
11. Srinivasan S.R., Myers L., and Berenson G.S. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart study. Hypertension 48 (2006) 33-39
12. Grotto I., Grossman E., Huerta M., and Sharabi Y. Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 48 (2006) 254-259
13. Juonala M., Viikari J.S.A., Ronnemaa T., et al. Elevated blood pressure in adolescent boys predicts endothelial dysfunction: The Cardiovascular Risk in Young Finns study. Hypertension 48 (2006) 424-430
14. Lande M.B., Carson N.L., Roy J., and Meagher C.C. Effects of childhood primary hypertension on carotid intima-media thickness: a matched controlled study. Hypertension 48 (2006) 40-44
15. Drukteinis J., Roman M.J., Fabsitz R.R., et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults. The Strong Heart study. Circulation 115 (2007) 221-227
16. Hsia J., Margolis K.L., Eaton C.B., et al., Women's Health Initiative Investigators. Prehypertension and Cardiovascular Disease Risk in the Women's Health Initiative. Circulation 115 (2007) 855-860
17. Zhang Y., Lee E.T., Devereux R.B., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart study. Hypertension 47 (2006) 410-414
18. Duprez D.A., Florea N.D., Jones K., and Cohn J.N. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities-the DETECTIV pilot study. J Am Coll Cardiol 50 (2007) 835-839
19. Williams B. Hypertension in the young-preventing the evolution of disease versus prevention of clinical events. J Am Coll Cardiol 50 (2007) 840-842
20. Rizzoni D., Porteri E., Guelfi D., et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 103 (2001) 1238-1244
21. Mathiassen O.N., Buus N.H., Sihm I., et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 25 (2007) 1021-1026
22. Erdogan D., Yildirim I., Ciftci O., et al. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 115 (2007) 593-599
23. Witt N., Wong T.Y., Hughes A.D., et al. Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension 47 (2006) 975-981
24. Yambe M., Tomiyama H., Yamada J., et al. Arterial stiffness and progression to hypertension in Japanese male subjects with high normal blood pressure. J Hypertens 24 (2007) 87-93
25. de Simone G., Schillaci G., Chinali M., et al. Estimate of white-coat effect and arterial stiffness. J Hypertens 25 (2007) 827-831
26. Leoncini G., Ratto E., Viazzi F., et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension 48 (2006) 397-403
27. Scuteri A., Tesauro M., Appolloni S., et al. Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens 25 (2007) 1035-1040
28. Hansen T.W., Staessen J.A., Torp-Pedersen C., et al. Ambulatory arterial stiffness index predicts stroke in a general population. J Hypertens 24 (2006) 2247-2253
29. Dolan E., Thijs L., Li Y., et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome study. Hypertension 47 (2006) 365-370
30. Ratto E., Leoncini G., Viazzi F., et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. J Hypertens 24 (2006) 2033-2038
31. Rodriguez C.J., Lin R., Sacco R.L., et al. Prognostic implications of left ventricular mass among Hispanics. The Northern Manhattan study. Hypertension 48 (2006) 87-92
32. Heckbert S.R., Post W., Pearson G.D.N., et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging. The Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 48 (2006) 2285-2292
33. Palmieri V., Okin P.M., de Simone G., et al. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 25 (2007) 1079-1085
34. Zakopoulos N., Tsivgoulis G.T., Barlas G., et al. Impact of the time rate of blood pressure variation on left ventricular mass. J Hypertens 24 (2006) 2071-2077
35. Salles G., Cardoso C., Nogueira A.R., Bloch K., and Muxfeldt E. Importance of the electrocardiographic strain pattern in patients with resistant hypertension. Hypertension 48 (2006) 437-442
36. Dhingra R., Pencina M.J., Wang T.J., et al. Electrocardiographic QRS duration and the risk of congestive heart failure-the Framingham Heart study. Hypertension 47 (2006) 861-867
37. Candida M., Borges C., Colombo R.C.R., et al. Longitudinal mitral annulus velocities are reduced in hypertensive subjects with or without left ventricle hypertrophy. Hypertension 47 (2006) 854-860
38. Solomon S.D., Janardhanan R., Verma A., et al., Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369 (2007) 2079-2087
39. Aksnes T.A., Flaa A., Strand A., and Kjeldsen S.E. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens 25 (2007) 15-23
40. Abhayaratna W.P., Seward J.B., Appleton C.P., et al. Left atrial size physiologic determinants and clinical applications. J Am Coll Cardiol 47 (2006) 2357-2363
41. Okin P.M., Wachtell K., Devereux R.B., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296 (2006) 1242-1248
42. Wachtell K., Okin P.M., Olsen M.H., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. Circulation 116 (2007) 700-705
43. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
44. Lee D.S., Austin P.C., Rouleau J.L., et al. Predicting mortality among patients hospitalized for heart failure. JAMA 290 (2003) 2581-2587
45. Ingelsson E., Bjorklund-Bodegard K., Lind L., and Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 295 (2006) 2859-2866
46. Adams Jr. H.P., del Zoppo G., Alberts M.J., et al. Guidelines for the early management of adults with ischemic stroke. Circulation 115 (2007) e478-e534
47. Broderick J., Connolly S., Feldmann E., et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update. Stroke 38 (2007) 2001-2023
48. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37 (2006) 2024-2029
49. Hirata K., Yaginuma T., O'Rourke M.F., and Kawakami M. Age-related changes in carotid artery flow and pressure pulses possible implications for cerebral microvascular disease. Stroke 37 (2006) 2552-2556
50. Willmot M., Ghadami A., Whysall B., et al. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension 47 (2006) 1209-1215
51. Zhang H., Thijs L., and Staessen J.A. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 48 (2006) 187-195
52. Paul S.L., and Thrift A.G. Control of hypertension 5 years after stroke in the North East Melbourne Stroke Incidence Study. Hypertension 48 (2006) 260-265
53. Peila R., White L.R., Masaki K., Petrovitch H., and Launer L.J. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37 (2006) 1165-1170
54. Hanon O., Pequignot R., Seux M.L., et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 24 (2006) 2101-2107
55. Almgren T., Wilhelmsen L., Samuelsson O., et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 25 (2007) 1311-1317
56. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
57. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
58. Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of trials of hypertension prevention. BMJ 334 (2007) 885-892
59. He F.J., and MacGregor G.A. Importance of salt in determining blood pressure in children meta-analysis of controlled trials. Hypertension 48 (2006) 861-869
60. McFarlane S.I., von Gizycki H., Salifu M., et al. Alcohol consumption and blood pressure in the adult US population: assessment of gender-related effects. J Hypertens 25 (2007) 965-970
61. Beilin L.J., and Puddey I.B. Alcohol and hypertension-an update. Hypertension 47 (2006) 1035-1038
62. Gangwisch J.E., Heymsfield S.B., Boden-Albala B., et al. Short sleep duration as a risk factor for hypertension: analyses of the First National Health and Nutrition Examination Survey. Hypertension 47 (2006) 833-839
63. Peppard P.E., Young T., Palta M., and Sktarud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 (2000) 1378-1384
64. Norman D., Loredo J.S., Nelesen R.A., et al. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 47 (2006) 840-845
65. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
66. Williams B., Poulter N.R., Brown M.J., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
67. Chapman N., Dobson J., Wilson S., et al., Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
68. Lane D.A., Shah S., and Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25 (2007) 891-894
69. Sharabi Y., Adler E., Shamis A., et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19 (2006) 750-755
70. Zillich A.J., Garg J., Basu S., Bakris G.L., and Carter B.L. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48 (2006) 219-224
71. Staessen J.A., Li Y., and Richart T. Oral renin inhibitors (erratum in: Lancet 2006;368:2124). Lancet 368 (2006) 1449-1456
72. Gradman A.H., Schmieder R.E., Lins R.L., et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
73. Menard J., and Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 25 (2007) 1775-1782
74. Schmieder R.E. The potential role of prorenin in diabetic nephropathy. J Hypertens 25 (2007) 1323-1326
75. Oparil S., Yarows S.A., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370 (2007) 221-229
76. Ambuhl P.M., Tissot A.C., Fulurija A., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25 (2007) 63-72
77. Menard J. A vaccine for hypertension?. J Hypertens 25 (2007) 41-46
78. Macklin E.A., Wayne P.M., Kalish L.A., et al. Stop Hypertension With Acupuncture Research (SHARP). Hypertension 48 (2006) 838-845
79. Flachskampf F.A., Gallasch J., Gefeller O., et al. Randomized trial of acupuncture to lower blood pressure. Circulation 115 (2007) 3121-3129
80. Masuyama H., Tsuruda T., Kato J., et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48 (2006) 972-978
81. Bakris G.L., Bank A.J., Kass D.A., et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17 (2004) 23S-30S
82. Zieman S.J., Melenovsky V., Clattenburg L., et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25 (2007) 577-583
83. Shores J., Berger K.R., Murphy E.A., and Pyeritz R.E. Progression of aortic dilatation and the benefit of long term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330 (1994) 1335-1341
84. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
85. Ahimastos A.A., Aggarwal A., D'Orsa K.M., et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome-a randomized controlled trial. JAMA 298 (2007) 1539-1547
86. Lacro R.V., Dietz H.C., Wruck L.M., et al. Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154 (2007) 624-631
87. Mahmud A., and Feely J. Low-dose quadruple antihypertensive combination more efficacious than individual agents-a preliminary report. Hypertension 49 (2007) 272-275
88. Lee J.K., Grace K.A., and Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296 (2006) 2563-2571
89. Strazzullo P., Kerry S.M., Barbato A., et al. Do statins reduce blood pressure?. A meta-analysis of randomized, controlled trials. Hypertension 49 (2007) 792-798
90. Williams B., and O'Rourke M. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens 15 Suppl 1 (2001) S69-S73
91. Mochizuki S., Dahlöf B., Shimizu M., et al., Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (2007) 1431-1439
92. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
93. Julius S., Weber M.A., Kjeldsen S.E., et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48 (2006) 385-391
94. Leenen F.H.H., Nwachuku C.E., Black H.R., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 48 (2006) 1-11
95. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
96. Higgens B., Williams B., and Guideline Development Group. Pharmacological management of hypertension. Clin Med 7 (2007) 612-616
97. Williams B. Evolution of hypertensive disease: a revolution in guidelines. Lancet 368 (2006) 6-7
98. Wiysonge C., Bradley H., Myose B., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 1 (2007) CD002003
99. Bangalore S., Messerli F.H., Kostis J.B., and Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572
100. Williams B. Beta-blockers and the treatment of hypertension. J Hypertens 25 (2007) 1351-1353
101. Lindholm L.H., Carlberg B., and Samuelsson O. Beta blockers in primary hypertension: do age and type of beta-blocker matter?. J Hypertens 24 (2006) 2143-2145
102. Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation 115 (2007) 1973-1974
103. Scholze J., Grimm E., Herrmann D., Unger T., and Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 115 (2007) 1991-1998
104. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1105-1187
105. Mendis S., Lindholm L.H., Mancia G., et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 25 (2007) 1578-1582
106. Rosendorff C., Black H.R., Cannon C.P., et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115 (2007) 2761-2788
107. Dworkin L.D. Controversial treatment of atherosclerotic renal vascular disease. Hypertension 48 (2006) 350-356
108. Seely E.W., and Maxwell C. Chronic hypertension in pregnancy. Circulation 115 (2007) e188-e190
109. Chobanian A.V. Isolated systolic hypertension in the elderly. N Engl J Med 357 (2007) 789-796
110. Reisch N., Peczkowska M., Januszewicz A., and Neumann H.P.H. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 24 (2006) 2331-2339
111. Vaclavi{dotless}k J., Stejskal D., Lacnak B., et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertension 25 (2007) 1427-1431
112. Wilson S.L., and Poulter N.R. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertension 24 (2006) 1457-1469
113. Mancia G., Bousquet P., Elghozi J.L., et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 25 (2007) 909-920
114. Wong T., and Mitchell P. The eye in hypertension. Lancet 369 (2007) 425-435
115. Messerli F.H., Williams B., and Ritz E. Essential hypertension. Lancet 370 (2007) 591-603